ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 1, Pages 13-21
Publisher
Oxford University Press (OUP)
Online
2014-08-13
DOI
10.1093/annonc/mdu378
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
- (2014) Lee S. Schwartzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification byKRASMutations in Advanced Colorectal Cancer
- (2013) Issa J. Dahabreh et al. ANNALS OF INTERNAL MEDICINE
- Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
- (2013) D J Jonker et al. BRITISH JOURNAL OF CANCER
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
- (2013) Matthew T Seymour et al. LANCET ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Explaining the Unexplainable: EGFR Antibodies in Colorectal Cancer
- (2012) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab
- (2012) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer
- (2012) Ajay S. Behl et al. JNCI-Journal of the National Cancer Institute
- Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
- (2011) Claire L. Vale et al. CANCER TREATMENT REVIEWS
- A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer
- (2011) Barbara-Ann Adelstein et al. EUROPEAN JOURNAL OF CANCER
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started